Related Experiment Videos
[Infliximab treatment for chronic sarcoidosis--a case series]
F Jounieaux1, C Chapelon, D Valeyre
1Service de pneumologie et immuno-allergologie, clinique des maladies respiratoires, centre de compétence des maladies pulmonaires rares, hôpital Albert-Calmette, CHRU de Lille, boulevard du Pr-Leclercq, 59037 Lille cedex, France.
Revue Des Maladies Respiratoires
|September 25, 2010
Summary
Infliximab shows effectiveness in treating chronic sarcoidosis, particularly for lung and skin involvement. However, frequent and severe side effects necessitate careful consideration and potential restriction to clinical trials.
Area of Science:
- Immunology
- Pulmonology
- Dermatology
Context:
- Chronic sarcoidosis presents significant therapeutic challenges.
- Management often involves multiple immunosuppressive agents and corticosteroids.
Purpose:
- To evaluate the efficacy and tolerability of infliximab in patients with chronic sarcoidosis.
- To assess infliximab's impact on organ involvement and corticosteroid dosage.
Summary:
- This retrospective study analyzed 31 chronic sarcoidosis patients treated with infliximab.
- A 62% response rate was observed across involved organs, with notable efficacy in pulmonary (65%) and cutaneous (67%) sarcoidosis.
- The corticosteroid-sparing effect was minimal, and 41.9% of patients experienced side effects, with 7/13 being severe.
Impact:
- Infliximab demonstrates potential for chronic sarcoidosis treatment, especially in specific organ manifestations.
- The high incidence of severe side effects suggests cautious use and the need for further research.
- Current evidence supports restricting infliximab use to clinical trials for defining optimal indications.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...